论文信息 - LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study - 字舞流文

LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

P. Ascierto | P. Queirolo | M. Mandalà | M. Guida | I. Melero | P. Rutkowski | C. Lebbé | E. Maiello | H. Helgadottir | D. Giannarelli | V. Ferraresi | P. Ferrucci | M. Guidoboni | G. Palmieri | R. Dummer | A. Grimaldi | V. Sileni | A. Fernandez | M. Fierro | M. D. Vecchio